SCHEMBL6447634

SCHEMBL6447634

C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2c(C(=N)NO)ccc(F)c12

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.58
CYP2C19 P33261 6/20 0.58
CYP2C9 P11712 5/20 0.58
CYP3A4 P08684 3/20 0.55
GHSR Q92847 5/20 0.40
PARP1 P09874 2/20 0.40
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CPS1 P31327 1/20 0.36
SLC6A7 Q99884 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2B6 P20813 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6447630 1.00 CYP2D6 (0.58) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6443731 0.90 CYP2C19 (0.63) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6443726 0.90 CYP2C19 (0.63) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6441267 0.89 CYP2C19 (0.62) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6441264 0.89 CYP2C19 (0.62) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6441531 0.89 CYP2C19 (0.51) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6441534 0.89 CYP2C19 (0.51) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL7661695 0.87 CYP2C19 (0.62) CYP2D6CYP2C19CYP2C9CYP3A4GHSR
SCHEMBL6449947 0.87 CYP2C9 (0.50) CYP2D6CYP2C19CYP2C9CYP3A4L3MBTL1
SCHEMBL6443879 0.86 CYP2C19 (0.58) CYP2D6CYP2C19CYP2C9CYP3A4GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA CYP2D6 831/4885CYP2C19 1624/4885CYP2C9 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.